ORIC® Pharmaceuticals Presents Potential Best-in-Class Data for Enozertinib in 1L NSCLC Patients with EGFR Atypical Mutations at ESMO Congress 2026 and Plans to Advance Enozertinib into a Global Phase 3 Trial
Key Highlights
- ➤84% confirmed systemic ORR reported for enozertinib in 1L EGFR atypical NSCLC
- ➤70% confirmed intracranial ORR reported, including multiple intracranial complete responses
- ➤88% six-month landmark PFS, with median PFS and response duration immature
- ➤Redwood-1 global Phase 3 trial expected to begin in 1H 2027
- ➤No treatment-related discontinuations or Grade 4 or 5 treatment-related adverse events
Expert Statements
Pratik S. Multani, M.D., Chief Medical Officer of ORIC Pharmaceuticals
“These enozertinib systemic and intracranial response data set a new benchmark in 1L EGFR atypical NSCLC”
Pratik S. Multani, M.D., Chief Medical Officer of ORIC Pharmaceuticals
“The data are particularly impressive given that nearly two-thirds of our patients had baseline brain metastases, which is more than double the rate seen in competitor datasets, and which has historically been associated with poorer outcomes.”
Jacob M. Chacko, M.D., President and Chief Executive Officer of ORIC Pharmaceuticals
“Supported by these potential best-in-class data and having successfully completed End-of-Phase 1 interactions with FDA, we are rapidly advancing enozertinib into a global Phase 3 registrational trial”
Jacob M. Chacko, M.D., President and Chief Executive Officer of ORIC Pharmaceuticals
“With rinzimetostat’s first Phase 3 trial in prostate cancer initiated earlier this year and enozertinib’s first Phase 3 trial in lung cancer planned for 1H 2027, ORIC has become a diversified, late-stage oncology company with two programs offering opportunities for broader development across indications with significant unmet need and meaningful commercial potential.”
In a 1L EGFR atypical population with more than double the rate of baseline CNS metastases as competitor datasets, enozertinib demonstrates a potential best-in-class 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with multiple intracranial complete responses
88% 6-month landmark PFS compares favorably to current standards of care and to investigational therapies; follow-up ongoing with majority of patients continuing on treatment
Get started
Create a free account to read the full story.